Skip to main content
NRXP
NASDAQ Life Sciences

Hope Therapeutics, NRXP 子公司，与 Emobot 合作部署 AI 驱动的抑郁症监测

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$2.25
Mkt Cap
$72.418M
52W Low
$1.58
52W High
$3.84
Market data snapshot near publication time

summarizeSummary

Hope Therapeutics, NRx Pharmaceuticals 的子公司，宣布与 Emobot Health 建立战略合作伙伴关系，将其 AI 驱动的 "抑郁症体温计" 整合到其干预精神病学网络中。该技术旨在被动监测患者的情绪状态，检测早期治疗反应，并预防难治性抑郁症的复发。这种运营增强可能会显著改善患者的治疗效果和留存率，可能加强 Hope Therapeutics 的市场地位。该消息提供了公司近期 "持续经营" 警告和重大股权稀释后的积极运营更新，表明其子公司产品的持续进展。投资者应该关注成功实施及其对患者成功率或收入产生的任何可衡量的影响。

在该公告发布时，NRXP的交易价格为$2.25，交易所为NASDAQ，所属行业为Life Sciences，市值约为$7241.8万。 52周交易区间为$1.58至$3.84。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed NRXP - Latest Insights

NRXP
Apr 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
FDA Gives Positive Feedback on NRx Pharma's Preservative-Free Ketamine, Targets Summer 2026 Approval
Sentiment: Positive
View Wiseek Article
NRXP
Apr 20, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Presidential Order to Fast-Track Psychedelic Drug Approvals Directly Benefits NRx Pharmaceuticals
Sentiment: Positive
View Wiseek Article
NRXP
Apr 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
NRx Pharma's Preservative-Free Ketamine Nears FDA Approval with Minor Labeling Feedback
Sentiment: Positive
View Wiseek Article
NRXP
Mar 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Hope Therapeutics, NRXP Subsidiary, Partners with Emobot to Deploy AI-Powered Depression Monitoring
Sentiment: Positive
View Wiseek Article
NRXP
Mar 24, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
7
Stockholders Approve Significant Increase in Annual Incentive Plan Share Reserve
Sentiment: Negative
View Wiseek Article
NRXP
Mar 23, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
8
NRX Pharmaceuticals Reports Going Concern, Massive Dilution, and Key Regulatory Progress in Annual 10-K
Sentiment: Negative
View Wiseek Article
NRXP
Mar 16, 2026, 7:36 AM EDT
Source: Reuters
Importance Score:
9
FDA Confirms Clear, Accelerated NDA Path for NRX-100 by June 2026, No New Trials Required
Sentiment: Positive
View Wiseek Article
NRXP
Feb 23, 2026, 5:00 PM EST
Filing Type: DEF 14A
Importance Score:
8
NRX Pharmaceuticals Seeks Shareholder Approval for Substantial Increase in Equity Incentive Plan Share Reserve
Sentiment: Negative
View Wiseek Article
NRXP
Feb 17, 2026, 9:21 AM EST
Filing Type: 8-K
Importance Score:
9
NRX Pharmaceuticals Secures Clear FDA Path for Full NDA Approval of NRX-100 with Broader Indication
Sentiment: Positive
View Wiseek Article
NRXP
Feb 17, 2026, 9:20 AM EST
Filing Type: 424B5
Importance Score:
9
NRX Pharmaceuticals Announces Highly Dilutive $20M At-The-Market Equity Offering
Sentiment: Negative
View Wiseek Article